Acute Respiratory Distress Syndrome (ards) Therapeutics - Pipeline Assessment And Market Forecasts T

Acute Respiratory Distress Syndrome (ards) Therapeutics - Pipeline Assessment And Market Forecasts T

By:


GlobalData valued the global acute respiratory distress syndrome (ARDS) therapeutics market at
$576.6m in 2010. The market is expected to grow at a compound annual growth rate (CAGR) of 2.4% to
reach $682.6m in 2017. The steady growth is primarily attributed to the low incidence of the disease and a lack of approved drugs on the market. The competitive landscape currently consists of generic and offlabel drugs.

GlobalDatas research indicates that the ARDS pipeline is weak, with 12 molecules in the different phases of development. First-in-class molecules have distinct advantages over current drug treatment options in terms of disease management. The unmet need of the ARDS market is high as there are no approved drugs currently on the market. Treatment currently relies on off-label drugs such as Levaquin
(levofloxacin), Nimbex (cisatracurium besylate) and generic drugs such as lorazepam and
methylprednisolone. The market subsequently needs therapies offering better results in terms of safety
and efficacy.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Acute-Respiratory-Distress-Syndrome-%28ARDS%29-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

The existing market landscape shows weak competition, due to the lack of approved drugs for the
treatment of ARDS. The market is dominated by off-label treatment, such as Levaquin, Nimbex, and other generics such as methylprednisolone, clindamycin and lorazepam. The market scenario is expected to change with the launch of new therapies, such as tissue factor (TF) antagonists, CD modulators, p38 kinase inhibitors and DNA polymerase inhibitors.

GlobalData analysis shows that the ARDS therapeutics pipeline is weak, with only 12 molecules in the
different phases of development. Although there are eight first-in-class molecules, these are mostly in the early stages of development or in pre-clinical trials. Their impact on the market is subsequently not
expected to be seen during the forecast period to 2017. There are currently no Phase III molecules in the
pipeline. Consequently, the pipeline for the ARDS therapeutics market is weak and is not expected to
greatly impact the market during the forecast period.

GlobalData, the industry analysis specialist, has released its new report, Acute Respiratory Distress
Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2017. The report is
an essential source of information and analysis on the global ARDS therapeutics market. The report
identifies the key trends shaping and driving the global ARDS therapeutics market. The report also
provides insights on the prevalent competitive landscape and the emerging players expected to
significantly alter the market positioning of the current market leaders. Most importantly, the report
provides valuable insights on the pipeline products within the global ARDS therapeutics sector. This
report is built using data and information sourced from proprietary databases, primary and secondary
research and in-house analysis by GlobalDatas team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Acute-Respiratory-Distress-Syndrome-%28ARDS%29-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

Visit our report store: http://www.globaldata.com

For more details contact:

pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782


About the Author:
GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.



Article Originally Published On: http://www.articlesnatch.com


Tags: , ,

|

Loading...
Related....
Videos...

Recent Press-Releases Articles

Comments

Still can't find what you are looking for? Search for it!

Loading

Site Navigation:

Copyright 2005-2011 ArticleSnatch, LLC - All Rights Reserved.
Privacy Policy | Terms of Service.